Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Bull Case How might positive itepekimab data impact Regeneron’s valuation? Positive data from the itepekimab COPD trials could significantly boost Regeneron’s prospects and stock valuation.

Itepekimab is a drug developed by Regeneron using its proprietary VelocImmune technology. It is a lab-engineered antibody designed to block a protein in the body called IL-33, which plays a role ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faced a turbulent week as its shares plunged 17%, despite announcing encouraging results from a Phase 3 trial of itepekimab for chronic obstructive ...

The AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic obstructive pulmonary disease (COPD) met the primary endpoint of a statistically significant ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive ...

Itepekimab is currently being evaluated in other trials, including chronic rhinosinusitis without nasal polyps, chronic rhinosinusitis with nasal polyps and non-cystic fibrosis bronchiectasis.